For people struggling with both diabetes and a common type of heart failure, the weight-loss drug Wegovy may do more for their health than help them shed pounds, new research suggests.
Apr 9, 2024
0
2
A chemical modification in the HIV-1 RNA genome whose function has been a matter of scientific debate is now confirmed to be key to the virus's ability to survive and thrive after infecting host cells, a new study has found.
Apr 11, 2024
0
36
The U.S. Food and Drug Administration has approved Winrevair (sotatercept-csrk) as an injectable treatment for pulmonary arterial hypertension (PAH) in adults.
Mar 29, 2024
0
1
Recent research from the University of Eastern Finland sheds light on the significance of the glucocorticoid receptor in drug-resistant prostate cancer, showing that the development of drug resistance could be prevented by ...
Apr 10, 2024
0
5
Bedsores—also known as pressure injuries—are the fastest rising hospital-acquired condition, according to the U.S. Agency for Healthcare Research in Quality, and as a result have become the second most common reason for ...
Apr 10, 2024
0
2
A study published in Health Data Science introduces an end-to-end deep learning framework, known as Knowledge-Empowered Drug Discovery (KEDD), aimed at revolutionizing the field of drug discovery. This innovative framework ...
Mar 29, 2024
0
1
Researchers at Weill Cornell Medicine have discovered a protein called SEL1L that plays a critical role in clearing collagen from tissue, and that may be a therapeutic target to help prevent fibrosis, scar tissue that interferes ...
Mar 26, 2024
0
16
Bart Klion, 95, and his wife, Barbara, faced a tough choice in January: The upstate New York couple learned that this year they could keep either their private, Medicare Advantage insurance plan—or their doctors at Saratoga ...
Apr 8, 2024
0
4
Researchers from the University of Birmingham, U.K., are creating a new 'lollipop' diagnostic for mouth cancer using a novel smart hydrogel.
Mar 21, 2024
0
5
A safe and effective medication designed to prevent mild-to-moderate COVID-19 infections from becoming more dangerous has been available for almost two years. But recent studies have shown many patients eligible for the drug—Paxlovid—haven't ...
Apr 1, 2024
0
1
